This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (1)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Dermatologic Disorders  • Neoplasms  • Drug Therapy  • Drug Therapy, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

Emmanuella Guenova, MD; Gisela Metzler, MD; Wolfram Hoetzenecker, MD, PhD; Mark Berneburg, MD; Martin Rocken, MD

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Replacement of mycophenolate mofetil, cyclosporine, or tacrolimus by sirolimus results in regression of Kaposi's sarcoma (KS) in organ transplant recipients.^1-3 In these patients, clearance from KS might result either from reduced immunosuppression or from the direct antiangiogenic effects of sirolimus.

Report of a Case

Herein we describe a 62-year-old man with disseminated Mediterranean KS that regressed almost completely during sirolimus therapy at a blood concentration of 6 ng/mL. The heterosexual, immunocompetent patient tested negative for both human immunodeficiency virus 1 and human immunodeficiency virus 2. However, he had 17 disseminated KS lesions that continuously erupted after excision of 2 single KS lesions that tested positive for human herpesvirus 8 and the D2-40 antibody (which is raised against M2A, an oncofetal antigen, and has been used as a marker for lymphatic endothelium). Owing to the large number of KS . . . [Full Text of this Article]

Comment

AUTHOR INFORMATION


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Dual Inhibition of PI3K{alpha} and mTOR as an Alternative Treatment for Kaposi's Sarcoma
Chaisuparat et al.
Cancer Res. 2008;68:8361-8368.
ABSTRACT | FULL TEXT